SAN DIEGO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Greece has granted Apricus' commercialization partner ...
 |
| READ THE ORIGINAL POST AT www.nasdaq.com |
